Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Paz-Ares, L.Goto, Y.Lim, W. D. T.Halmos, B.Cho, B. C.Dols, M. CoboGonzalez-Larriba, J. L.Zhou, C.Demedts, I.Atmaca, A.Baka, S.Mookerjee, B. P.Portella, S.Zhu, Z.Dharan, B.Reck, M.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/24516enCanakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III resultsconference outputopen access10.1016/j.annonc.2021.08.17991569-8041https://doi.org/10.1016/j.annonc.2021.08.1799700527702213